General Information of Drug (ID: DMXTYWJ)

Drug Name
Neovastat Drug Info
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 1 [1]
Renal cell carcinoma 2C90 Phase 1 [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
TTD Drug ID
DMXTYWJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
FP-025 DMH1NXO Asthma CA23 Phase 1 [3]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [4]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [4]
PMID29130358-Compound-Figure17(11) DMSZA9L N. A. N. A. Patented [4]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [5]
AZD1236 DML3RSF Chronic obstructive pulmonary disease CA22 Discontinued in Phase 2 [6]
V85546 DMLFMSY Inflammation 1A00-CA43.1 Discontinued in Phase 1 [7]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [8]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [9]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [10]
DP-b99 DM97S10 Stroke 8B20 Phase 3 [11]
GS-5745 DMP8MDW Gastric adenocarcinoma 2B72 Phase 3 [12]
Andecaliximab DMLDB1X Gastric adenocarcinoma 2B72 Phase 3 [13]
BLZ-100 DMFKA4G Glioma 2A00.0 Phase 1/2 [14]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [4]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [4]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [4]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [4]
PMID29130358-Compound-Figure17(11) DMSZA9L N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [15]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [16]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [17]
Metastat DMTQ4PN Acne vulgaris ED80 Phase 1 [18]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [4]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [4]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [4]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [4]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [4]
PMID29130358-Compound-Figure18(14) DM7WXJ9 N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-12 (MMP-12) TTXZ0KQ MMP12_HUMAN Inhibitor [2]
Matrix metalloproteinase-2 (MMP-2) TTLM12X MMP2_HUMAN Inhibitor [2]
Matrix metalloproteinase-9 (MMP-9) TT6X50U MMP9_HUMAN Inhibitor [2]

References

1 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
2 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
3 Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445-7.
4 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
5 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
6 Clinical pipeline report, company report or official report of AstraZeneca (2009).
7 Clinical pipeline report, company report or official report of Vernalis.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
10 Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
11 DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
12 National Cancer Institute Drug Dictionary (drug id 747683).
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
15 AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
16 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
17 Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
18 Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.